Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

Gennaro Riccio, Giovanni Esposito, Emanuela Leoncini, Riccardo Contu, Gianluigi Condorelli, Massimo Chiariello, Paolo Laccetti, Silvana Hrelia, Giuseppe D'Alessio, Claudia De Lorenzo

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.

Original languageEnglish
Pages (from-to)3171-3178
Number of pages8
JournalFASEB Journal
Volume23
Issue number9
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Apoptosis
Fibrosis
Echocardiography
Poisons
In Situ Nick-End Labeling
DNA Fragmentation
Therapeutics
Ribonucleases
Bromides
Immunoblotting
Doxorubicin
Toxicity
Epitopes
Assays
Collagen
Fusion reactions
Immunoglobulin G
Cells
Staining and Labeling
Breast Neoplasms

Keywords

  • Heart failure
  • Her2
  • Herceptin
  • ImmunoRNase
  • Immunotherapy
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Molecular Biology

Cite this

Riccio, G., Esposito, G., Leoncini, E., Contu, R., Condorelli, G., Chiariello, M., ... De Lorenzo, C. (2009). Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB Journal, 23(9), 3171-3178. https://doi.org/10.1096/fj.09-131383

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. / Riccio, Gennaro; Esposito, Giovanni; Leoncini, Emanuela; Contu, Riccardo; Condorelli, Gianluigi; Chiariello, Massimo; Laccetti, Paolo; Hrelia, Silvana; D'Alessio, Giuseppe; De Lorenzo, Claudia.

In: FASEB Journal, Vol. 23, No. 9, 09.2009, p. 3171-3178.

Research output: Contribution to journalArticle

Riccio, G, Esposito, G, Leoncini, E, Contu, R, Condorelli, G, Chiariello, M, Laccetti, P, Hrelia, S, D'Alessio, G & De Lorenzo, C 2009, 'Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents', FASEB Journal, vol. 23, no. 9, pp. 3171-3178. https://doi.org/10.1096/fj.09-131383
Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB Journal. 2009 Sep;23(9):3171-3178. https://doi.org/10.1096/fj.09-131383
Riccio, Gennaro ; Esposito, Giovanni ; Leoncini, Emanuela ; Contu, Riccardo ; Condorelli, Gianluigi ; Chiariello, Massimo ; Laccetti, Paolo ; Hrelia, Silvana ; D'Alessio, Giuseppe ; De Lorenzo, Claudia. / Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. In: FASEB Journal. 2009 ; Vol. 23, No. 9. pp. 3171-3178.
@article{12ede6e6bc714ef6ae34169f81575f68,
title = "Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents",
abstract = "This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.",
keywords = "Heart failure, Her2, Herceptin, ImmunoRNase, Immunotherapy, Trastuzumab",
author = "Gennaro Riccio and Giovanni Esposito and Emanuela Leoncini and Riccardo Contu and Gianluigi Condorelli and Massimo Chiariello and Paolo Laccetti and Silvana Hrelia and Giuseppe D'Alessio and {De Lorenzo}, Claudia",
year = "2009",
month = "9",
doi = "10.1096/fj.09-131383",
language = "English",
volume = "23",
pages = "3171--3178",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

TY - JOUR

T1 - Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

AU - Riccio, Gennaro

AU - Esposito, Giovanni

AU - Leoncini, Emanuela

AU - Contu, Riccardo

AU - Condorelli, Gianluigi

AU - Chiariello, Massimo

AU - Laccetti, Paolo

AU - Hrelia, Silvana

AU - D'Alessio, Giuseppe

AU - De Lorenzo, Claudia

PY - 2009/9

Y1 - 2009/9

N2 - This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.

AB - This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.

KW - Heart failure

KW - Her2

KW - Herceptin

KW - ImmunoRNase

KW - Immunotherapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=70349317477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349317477&partnerID=8YFLogxK

U2 - 10.1096/fj.09-131383

DO - 10.1096/fj.09-131383

M3 - Article

C2 - 19417081

AN - SCOPUS:70349317477

VL - 23

SP - 3171

EP - 3178

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -